317results about How to "Useful in therapy" patented technology

This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.

The present invention provides novel compounds represented by formula I:

or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.

A curable composition for use in wound care comprising, apportioned between at least one Part A and at least one Part B: one or more alkenyl-group containing polymers (i) having at least one alkenyl group or moiety per molecule, one or more SiH-containing polymers (ii) having at least one Si—H unit per molecule; and a catalyst (iii) for curing by addition of alkenyl-containing polymer (i) to SiH-containing polymer (ii), Part A and Part B independently having viscosity at 23° C. in the range 5-300 Pa·s, preferably 10-100 Pa s, at a shearing rate of 10 s⁻¹, and when combined in one Part having cure time at 23° C. in the range from 0.5 min to 25 min, wherein when dispensed into a location about a wound dressing, said wound dressing overlying a wound site and skin thereabout, said dispensing being so as to intimately contact and overlie an edge of said dressing and skin about said edge, the composition cures in contact with said edge and skin at 32° C. to an elastomer exhibiting zero or low tack at a time in the range from 0.5 to less than 30 minutes, apparatus for use with said composition comprising dispensing apparatus or wound dressing, a kit comprising the same, and methods of dispensing and curing the same and of using the same in sealing a wound dressing and in treating a wound site of a human in need thereof.

Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I

The present invention provides methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death.

A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder:

A method of using specially designed a nanoparticles to contact and then cross the cell, nuclear and/or mitochondrial membrane of the target cell by generating a multitude of complex nanoparticle structures that resonate or vibrate at a specific frequency. Glutathione and/or other molecules or drugs are attached as molecular layers to the nanoparticle structures and the complex particle structures are delivered to the targeted cells. The glutathione and other molecules or drugs are then released from the nanoparticle structures in the destination target cell by using external radiation.

A method for reducing artifacts in an original computed tomography (CT) image of a subject, the original (CT) image being produced from original sinogram data. The method comprises detecting an artifact creating object in the original CT image; re-projecting the artifact creating object in the original sinogram data to produce modified sinogram data in which missing projection data is absent; interpolating replacement data for the missing projection data; replacing the missing projection data in the original sinogram data with the interpolated replacement data to produce final sinogram data; and reconstructing a final CT image using the final sinogram data to thereby obtain an artifact-reduced CT image.

The present invention provides a oxazole compound represented by Formula (1), or a salt thereof:

wherein R¹ is an aryl group which may have one or more substituents; R² is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y¹-A¹- or —Y²—C(═O)— wherein Y¹ is a group such as —C(═O)—, A¹ is a group such as a lower alkylene group, and Y² is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.

The present invention provides a compound represented by general formula (I):

or pharmaceutically acceptable salts thereof, wherein W is O, S(O)_m, CH₂ and the like; R¹ is halogen, lower alkyl, halo-lower alkyl, CN and the like; R³ is hydrogen and the like; R⁴ is hydrogen, halogen, alkyl, halo-lower alkyl, substituted alkyl, aryl, aralkyl, alkoxy, substituted alkoxy, alkanoyl, aroyl, —CONR⁷(R⁸), —S(O)_mR⁹, —SO₂NR⁷(R⁸) and the like; R⁵ is hydrogen, halogen, alkyl, substituted alkyl and the like; A is —N(R⁶)CO-A¹-COR¹⁰ and the like; pharmaceutical compositions containing them and their uses, which have a high affinity to human thyroid hormone receptors, in particular human thyroid hormone receptor β.

A system and a method of performing a frameless image-guided biopsy uses imaging, a six-dimensional robotic couch system, a laser guidance system, an optical distance indicator, and a needle control apparatus. A planning CT scan is made of the patient with stereotactic fiduciary markers to localize and produce digitally reconstructed radiographs. Two stereoscopic images are generated using an imaging device to visualize and identify a target tumor. The images are fused with the digitally reconstructed radiographs of the planning CT scan to process tumor location. The tumor location data are communicated to the movable robotic couch to position the target tumor of the patient at a known isocenter location. A biopsy needle is guided with a laser alignment mechanism towards the isocenter at the determined depth using a needle positioning apparatus and an Optical Distance Indicator, and a biopsy sample of the target tumor is obtained.

There are provided novel compounds of formula (I) wherein R1?, R4?. R5?, G1?, G2?, X, L, Y1?, Y2? and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors or neutrophil elastase.

A recoverable, safe and reliable valve stent for unidirectional flow of human lumen which can be implanted temporarily or for a long term and is used in the interventional therapy so as to obstruct from anisotropic flow, in the case of lung diseases. It comprises a cylindrical stent made up of memory alloy material. In particular, an elastic diaphragm is arranged inside the cylindrical stent and at least one gap is arranged on the diaphragm so that the spring piece is divided into a bendable section. One end of the cylindrical stent is provided with a fixed rear clip which is used to fix the alloy material making up the cylindrical stent. The rear clip is provided with screwthreads which can be connected with the conveyor. The stent in the present invention is in a structure without hook body, so the stent can be accurately positioned, adjusted and placed or recovered in double directions with strong anti-backflow ability.

The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

The invention relates to methods of obtaining compositions for generating multipotent hematopoietic stem progenitor cells comprising expansion of hematopoietic stem cells in the presence of HDACI and IDM. Methods of obtaining compositions enriched in hematopoietic megakaryocyte progenitor cells are also provided. Compositions enriched for stem cells and populations of cells obtained therefrom are also provided by the invention.

Described and claimed herein are methods for producing chemically stabilized Aβ protofibrillar aggregates, and compositions made therefrom. Compositions produced are useful in facilitating detailed studies of Aβ protofibril structure, fibril formation, and progression of Aβ related diseases, e.g., Alzheimers disease. In addition, chemically stabilized protofibrillar structures can be used as tools to generate and/or screen for antibodies specific for protofibrils. Antibodies specific for protofibrils can be used as diagnostic tools or as therapeutics in the diagnosis or treatment of, e.g., Alzheimer's disease. Finally, chemically stabilized protofibrillar structures can be used in the preparation of therapeutic or prophylactic vaccines.

Compounds having a structure of Formula I:

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R¹, R², R³, R⁴, M¹, M², X, L¹, L², J¹, J², a¹, a², b¹ and b² are as defined herein, and wherein at least one of M² or L² is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same.wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents (a) a saturated hydrocarbon ring, (b) an unsaturated hydrocarbon ring, (c) a saturated heterocyclic ring or (d) an unsaturated heterocyclic ring, all of which may have a substituent group.

A breathable electrical heater element for a topical application device such as a wound dressing or a therapeutic heating pad is disclosed. The heater element is formed by photochemically etching a track pattern onto a porous metallised fabric (e.g. nickel coated woven polyester). The heater element has a skin or wound contact layer laminated to the front face of the heater element. An adhesive layer is laminated to the back face of the heater element. The adhesive layer forms an overhang to provide an adhesive border around the wound contact layer to adhere the device to the skin of a patient. Therapeutically active drugs (optionally microencapsulated) may be incorporated into the skin or wound contact layer. Operation of the heater element causes the skin or wound contact layer to release the active drugs to the skin or wound of the patient. Appropriate control of the temperature of the heater element allows control of the release of the active drugs.

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R¹, R², R⁵, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.